Compare Amgen, Inc. (AMGN) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs AST SpaceMobile Inc — how do they compare? Amgen, Inc. trades at $414.3 (market cap $224.14B), while AST SpaceMobile Inc trades at $71.93 (market cap $20.54B). The key difference: Amgen, Inc. is far larger — about 10.9× AST SpaceMobile Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| AMGN | ASTS | |
|---|---|---|
Market Cap | $224.14B | $20.54B |
Sector | Health | Media |
52-Week High | $417.20 | $133.09 |
52-Week Low | $271.18 | $36.91 |
Enterprise Value | $267.45B | $21.25B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
ASTS trades at $68.76, down 4.42% today, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 revenue of $31.5 million, missing estimates, but reaffirmed full-year guidance of $150-200 million. Financials show significant losses, with a net income margin of -573.67% in 2026, though revenue growth is accelerating. Analyst consensus is mixed with a $84.63 price target, and recent news highlights partnerships with SpaceX and expansion in Europe.
The outlook is speculative with high growth potential from satellite network deployment, but substantial cash burn and execution risks persist. Investment opportunity lies in the $1.3 billion backlog and commercial service rollout, while risks include continued losses, high valuation multiples, and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
